Free Trial

AstraZeneca (AZN) Competitors

AstraZeneca logo
$75.36 -0.61 (-0.80%)
Closing price 04:00 PM Eastern
Extended Trading
$75.30 -0.06 (-0.08%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AZN vs. NVS, NVO, SNY, GSK, TAK, ARGX, ONC, INSM, BNTX, and TEVA

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novartis (NVS), Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

AstraZeneca vs. Its Competitors

AstraZeneca (NASDAQ:AZN) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Novartis has lower revenue, but higher earnings than AstraZeneca. Novartis is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca$54.07B4.32$7.04B$2.6628.33
Novartis$50.32B5.16$11.94B$6.8717.90

AstraZeneca currently has a consensus target price of $86.00, suggesting a potential upside of 14.12%. Novartis has a consensus target price of $120.33, suggesting a potential downside of 2.13%. Given AstraZeneca's stronger consensus rating and higher possible upside, equities research analysts plainly believe AstraZeneca is more favorable than Novartis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Novartis
3 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.00

Novartis has a net margin of 25.64% compared to AstraZeneca's net margin of 14.68%. Novartis' return on equity of 41.08% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca14.68% 32.84% 12.87%
Novartis 25.64%41.08%16.83%

20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, AstraZeneca had 5 more articles in the media than Novartis. MarketBeat recorded 24 mentions for AstraZeneca and 19 mentions for Novartis. Novartis' average media sentiment score of 1.37 beat AstraZeneca's score of 1.18 indicating that Novartis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
19 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novartis
16 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

AstraZeneca has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

AstraZeneca pays an annual dividend of $1.01 per share and has a dividend yield of 1.3%. Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.1%. AstraZeneca pays out 38.0% of its earnings in the form of a dividend. Novartis pays out 37.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Novartis beats AstraZeneca on 12 of the 19 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$233.72B$3.11B$5.74B$10.35B
Dividend Yield1.30%2.36%5.53%4.58%
P/E Ratio28.3320.9076.3526.43
Price / Sales4.32253.83466.9191.04
Price / Cash12.3146.3537.4661.85
Price / Book5.729.8313.186.39
Net Income$7.04B-$52.73M$3.29B$271.22M
7 Day Performance-3.00%4.85%2.50%2.78%
1 Month Performance-6.93%6.37%4.60%7.35%
1 Year Performance-1.96%19.15%73.81%29.64%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
3.0554 of 5 stars
$75.36
-0.8%
$86.00
+14.1%
-1.5%$233.72B$54.07B28.3394,300Positive News
NVS
Novartis
2.089 of 5 stars
$123.27
-0.7%
$120.33
-2.4%
+5.5%$260.40B$50.32B17.9475,883Positive News
NVO
Novo Nordisk A/S
4.223 of 5 stars
$55.62
+1.4%
$81.00
+45.6%
-51.9%$248.34B$42.12B15.2877,349Trending News
SNY
Sanofi
4.0219 of 5 stars
$46.62
-0.9%
$62.67
+34.4%
-18.4%$114.48B$44.46B11.2182,878
GSK
GSK
1.8574 of 5 stars
$40.31
-1.3%
$37.38
-7.3%
-0.9%$82.10B$40.10B18.6668,629Dividend Cut
TAK
Takeda Pharmaceutical
2.7783 of 5 stars
$15.08
-0.1%
N/A+1.0%$47.98B$30.09B50.2747,455
ARGX
argenex
4.1231 of 5 stars
$756.83
+0.1%
$784.32
+3.6%
+39.0%$46.32B$2.25B38.811,599Analyst Upgrade
ONC
BeOne Medicines
1.8327 of 5 stars
$332.27
+2.4%
$330.89
-0.4%
N/A$36.42B$3.81B-192.0611,000Gap Up
INSM
Insmed
3.0367 of 5 stars
$143.14
-1.9%
$139.86
-2.3%
+102.4%$30.26B$398.11M-25.071,271
BNTX
BioNTech
2.6832 of 5 stars
$97.88
+1.2%
$135.80
+38.7%
-13.1%$23.53B$2.98B-61.176,772Analyst Forecast
TEVA
Teva Pharmaceutical Industries
3.0668 of 5 stars
$18.90
-5.2%
$24.71
+30.8%
+9.7%$21.68B$16.63B-118.1336,830Analyst Forecast

Related Companies and Tools


This page (NASDAQ:AZN) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners